Skip to main content

Table 1 Rituximab in non-Hodgkin's lymphoma pivotal trial: infections

From: B cell non-Hodgkin's lymphoma: rituximab safety experience

Patients monitored throughout treatment and >1 year follow up
Despite B cell depletion, incidence of infection was not increased
Most infections were typical of those common in normal hosts
Predominantly bacterial
Seven episodes of grade 3 infections
No patients experienced grade 4 infections
  1. Data from McLaughlin and coworkers [1].